Research publications

Alfred Health research outcomes are published in a wide range of peer reviewed journals. 

Search or browse research publications by year, research area, publication type or keyword.

Clear filter
Publication Details
Victoria's surgical response to the COVID-19 pandemic

Drysdale, Henry Richard Edward; Watters, David Allan; Leang, Yit Jern; N J Thomson, Benjamin; Brown, Wendy Ann; Wilson, Andew

(2023), ANZ Journal of Surgery, 93(3), 476-486

DOI: 10.1111/ans.18311

Prospective, randomized, multicenter clinical study comparing a self-expanding covered stent to percutaneous transluminal angioplasty for treatment of upper extremity hemodialysis arteriovenous fistula stenosis

Dolmatch, Bart; Cabrera, Timoteo; Pergola, Pablo; Balamuthusamy, Saravanan; Makris, Angelo; Cooper, Randy; Moore, Erin; Licht, Jonah; Macaulay, Ewan; Maleux, Geert; Pfammatter, Thomas; Settlage, Richard A.; Cristea, Ecaterina; Lansky, Alexandra J; Goh, Ge

(2023), Kidney International, 104(1), 189-200

DOI: 10.1016/j.kint.2023.03.015

Is Metabolic Surgery Having an Identity Crisis?

Cohen, Ricardo Vitor; Lingvay, Ildiko; Le Roux, Carel W.; Sumithran, Kalpana Priyadarsini

(2023), Obesity Surgery, 33(10), 3327-3329

DOI: 10.1007/s11695-023-06786-x

Research output of radiologists in Australia and New Zealand

Clements, Warren; So, Joanne; Koukounaras, Jim; Lau, Gabes; Lukies, Matthew

(2023), Journal of Medical Imaging and Radiation Oncology, 67(7), 697-702

DOI: 10.1111/1754-9485.13548

Management of Spontaneous Retroperitoneal Haemorrhage Emphasises the Need for Nuanced Clinical Decision Making in Interventional Radiology

Clements, Warren; Lukies, Matthew

(2023), CardioVascular and Interventional Radiology, 46, 701-702

DOI: 10.1007/s00270-023-03431-z

Complications in Interventional Radiology

Clements, Warren; Koukounaras, Jim

(2023), CVIR Endovascular, 6(1), 38

DOI: 10.1186/s42155-023-00388-5

A new subsection within JMIRO

Clements, Warren; Cheung, Andrew; Brown, Nicholas

(2023), Journal of Medical Imaging and Radiation Oncology, 64(4), 409-11

DOI: 10.1111/1754-9485.13514

Implementation of lasting changes to sustainability in Interventional Radiology is a top-down governance challenge

Clements, Warren

(2023), CVIR Endovascular, 6(1), 22

DOI: 10.1186/s42155-023-00371-0

Commentary on “Post-Embolization Hemoglobin Changes

Clements, Warren

(2023), CardioVascular and Interventional Radiology, 46, 626-627

DOI: 10.1007/s00270-023-03432-y

Understanding Leadership and its Vital Role in the Growth of Interventional Radiology

Clements, Warren

(2023), CardioVascular and Interventional Radiology, 46(4), 541-2

DOI: 10.1007/s00270-023-03365-6

The length of hospital stay following bariatric surgery in Australia

Chadwick, Chiara Nancy; Burton, Paul Robert; Brown, Dianne Lyndel; Holland, Jennifer; Campbell, Angus; Cottrell, Jenifer Lynn; Reilly, Jennifer; MacCormick, Andrew; Caterson, Ian; Brown, Wendy Ann

(2023), ANZ Journal of Surgery, 93(12), 2833-42

DOI: 10.1111/ans.18575

Clustering on longitudinal quality-of-life measurements using growth mixture models for clinical prognosis: Implementation on CCTG/AGITG CO.20 trial

Zhang J, Kong W, Hu P, Jonker D, Moore M, Ringash J, Shapiro J, Zalcberg J, Simes J, Tu D, O'Callaghan CJ, Liu G, Xu W

(2023), CANCER MEDICINE, 12(5), 6117-28

DOI: 10.1002/cam4.5341

A capability framework to inform the fundamental requirements for clinical trial unit development, growth and long term success in outer metropolitan and rural areas

Woollett, A., Duncan, J., Voskoboynik, M., Shackleton, M., Dooley, M., Blum, R., McPhee, N., Wright, T., Wong, Z. W., Dixon, J., & Jane, S. M

(2023), Contemporary clinical trials communications, 32, 101072

DOI: 10.1016/j.conctc.2023.101072

Immune-related adverse events secondary to immunotherapy in oncology

Yeoh, Hui-Ling; Freilich, Karen Belinda; Voskoboynik, Mark; Moore, Maggie; Andrews, Miles Cameron Gregory; Shackleton, Mark; Haydon, Andrew Mark Meurisse

(2023), Australian Journal of General Practice, 52(6), 378-385

DOI: 10.31128/AJGP-04-22-6408

Adjuvant Therapy of Nivolumab Combined With Ipilimumab Versus Nivolumab Alone in Patients With Resected Stage IIIB-D or Stage IV Melanoma (CheckMate 915)

Weber JS, Schadendorf D, Del Vecchio M, Larkin J, Atkinson V, Schenker M, Pigozzo J, Gogas H, Dalle S, Meyer N, Ascierto PA, Sandhu S, Eigentler T, Gutzmer R, Hassel JC, Robert C, Carlino MS, Di Giacomo AM, Butler MO, Muñoz-Couselo E, Brown MP, Rutkowski P, Haydon A, Grob JJ, Schachter J, Queirolo P, de la Cruz-Merino L, van der Westhuizen A, Menzies AM, Re S, Bas T, de Pril V, Braverman J, Tenney DJ, Tang H, Long GV

(2023), Journal of Clinical Oncology, 41(3), 517-27

DOI: 10.1200/JCO.22.00533

Evaluating sex as a predictive marker for response to bevacizumab in metastatic colorectal carcinoma: Pooled analysis of 3,369 patients in the ARCAD database

Margalit O, Harmsen WS, Shacham-Shmueli E, Voss MM, Boursi B, Wagner AD, Cohen R, Olswold CL, Saltz LB, Goldstein DA, Hurwitz H, Tebbutt NC, Kabbinavar FF, Adams RA, Chibaudel B, Grothey A, Yoshino T, Zalcberg J, de Gramont A, Shi Q, Lenz HJ

(2023), European Journal of Cancer, 178, 162-70

DOI: 10.1016/j.ejca.2022.10.022

Design, optimisation and standardisation of a high-dimensional spectral flow cytometry workflow assessing T-cell immunophenotype in patients with melanoma

Edwards JM, Andrews MC, Burridge H, Smith R, Owens C, Edinger M, Pilkington K, Desfrancois J, Shackleton M, Senthi S, van Zelm MC

(2023), Clinical & Translational Immunology, 12(9), e1466

DOI: 10.1002/cti2.1466

Treatment Characteristics and Real-World Progression-Free Survival in Patients With Unresectable Stage III NSCLC Who Received Durvalumab After Chemoradiotherapy: Findings From the PACIFIC-R Study

Girard N, Bar J, Garrido P, Garassino MC, McDonald F, Mornex F, Filippi AR, Smit HJM, Peters S, Field JK, Christoph DC, Sibille A, Fietkau R, Haakensen VD, Chouaid C, Markman B, Hiltermann TJN, Taus A, Sawyer W, Allen A, Chander P, Licour M, Solomon B

(2023), JOURNAL OF THORACIC ONCOLOGY, 18(2), 181-93

DOI: 10.1016/j.jtho.2022.10.003

Randomized, Double-Blind, Placebo-Controlled, Global Phase III Trial of Talimogene Laherparepvec Combined With Pembrolizumab for Advanced Melanoma

Chesney JA, Ribas A, Long GV, Kirkwood JM, Dummer R, Puzanov I, Hoeller C, Gajewski TF, Gutzmer R, Rutkowski P, Demidov L, Arenberger P, Shin SJ, Ferrucci PF, Haydon A, Hyngstrom J, van Thienen JV, Haferkamp S, Guilera JM, Rapoport BL, VanderWalde A, Diede SJ, Anderson JR, Treichel S, Chan EL, Bhatta S, Gansert J, Hodi FS, Gogas H

(2023), Journal of Clinical Oncology, 41(3), 528-40

DOI: 10.1200/JCO.22.00343

Updated cost-effectiveness analysis of lung cancer screening for Australia, capturing differences in the health economic impact of NELSON and NLST outcomes

Behar Harpaz S, Weber MF, Wade S, Ngo PJ, Vaneckova P, Sarich PEA, Cressman S, Tammemagi MC, Fong K, Marshall H, McWilliams A, Zalcberg JR, Caruana M, Canfell K

(2023), British Journal of Cancer, 128(1), 91-101

DOI: 10.1038/s41416-022-02026-8

20 21 22 23 24